Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
ASCO submitted in depth comments highlighting its concerns and recommending potential solutions in response to the 2019 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule.
ASCO has joined a letter led by the American Medical Association (AMA) to CMS opposing a recent notification from the agency that Medicare Advantage plans will be allowed to use step therapy protocols for physici
ASCO is committed to supporting cancer care providers and patients affected by natural disasters with resources and information. Due to the threat of Hurricane Florence, the society has assembled a list of resources to aid cancer patients and care providers in the states and regions affected, including resources provided by the Centers for Medicare and Medicaid Services (CMS), emergency contact information, and information on state societies.
ASCO has issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO's policy statement, "Addressing Financial Barriers to Patient Participation in Clinical Trials," also stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.
On Sept. 13, 2018, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITITM, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Read more. 
ASCO warns that provisions of the 2019 Medicare Physician Fee Schedule proposed rule will undermine access to cancer care for Medicare beneficiaries through a combination of payment reductions.
The number of international practices certified in delivering high-quality cancer care based on rigorous standards established by ASCO is increasing. The Medisprof Cancer Center in Romania joins six other practices in Brazil, Greece, and Spain in achieving ASCO’s Quality Oncology Practice Initiative (QOPI®) Certification. Medisprof Cancer Center, located in Cluj, Romania, is an outpatient hematology-oncology practice.
This year’s meeting will take place on September 23-24, 2018, at ASCO’s headquarters in the Washington, DC metro area. Register to attend now! Learn More.